Clinical Trial Update: Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating LNZ100 and LNZ101 for presbyopia has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia
• Refractive Error

Drugs mentioned

• LNZ100 (Aceclidine)
• LNZ101 (Aceclidine/Brimonidine)

Snippet

Sponsor: LENZ Therapeutics, Inc | Conditions: Presbyopia, Refractive Error | Phase 3 | Status: COMPLETED | Results posted: 2026-02-25